Agios Pharmaceuticals
NASDAQ: AGIOIncorporated in Delaware Β· Public Β· 3 known investors
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease. The company's approach is grounded in cellular metabolism research and involves close collaboration with patients and clinical partners.
Also known as AGIO Β· Agios Β· Agios Pharmaceutical Inc. Β· Agios Pharmaceuticals, Inc.
Investors Β· 3
Also in the syndicate Β· 1
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Competitors Β· 2
by search overlapCompanies competing with Agios Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline Β· 20
launches, deals, and filingsNews coverage reported that Agios shares fell nearly 7% after the company scrapped the tebapivat sickle cell disease program.
The company secured European Union approval for Pyrukynd (mitapivat) to treat adults with thalassemia.
The Emirates Drug Establishment of the UAE approved PYRUKYND (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia.
Commodore Capital disclosed in an SEC filing that it sold all 2,338,287 shares of Agios Pharmaceuticals during the fourth quarter, an estimated $93.86 million position that had been 4.6% of the fund's AUM.
$93.9M source β
The U.S. FDA approved AQVESME (mitapivat), an oral pyruvate kinase activator, for the treatment of anemia in adults with alpha- or beta-thalassemia.
Purchase and Sale Agreement dated October 27, 2022 between Agios Pharmaceuticals as seller and a set of purchasers, filed as an exhibit to a 10-K with certain information excluded as confidential.
The FDA approved mitapivat (PYRUKYND) as the first disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase deficiency; announcement dated February 17, 2022, with the Wikipedia text also referencing April 2022.
Brian Goff, recruited from Alexion, serves as CEO as of August 2022; Jacqualyn A. Fouse, Ph.D. has served as Chairman since 2022.
Agios completed the sale of its commercial, clinical and research-stage oncology portfolio to Servier for $1.8 billion in upfront cash, pivoting entirely to rare diseases.
$1.8B source β
Purchase and Sale Agreement by and among Agios Pharmaceuticals, Servier Pharmaceuticals, LLC and Servier S.A.S., dated December 20, 2020, filed as an exhibit to an 8-K and DEFA14A.
Underwritten public offering of 8,250,000 shares of common stock at $31.00 per share, for approximately $256 million in aggregate gross proceeds.
$256M source β
Agios filed an NDA with the FDA for ivosidenib for adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
Agios and Aurigene entered into an exclusive license agreement for novel small molecules directed at a cancer metabolism target.
Agios raised $250 million in a new stock offering in anticipation of FDA approval of its first cancer drug, enasidenib.
$250M source β
Agios announced its MTAP pathway research program as a development program and development candidate under its master research and collaboration agreement with Celgene.
The FDA accepted the New Drug Application and granted priority review for enasidenib in relapsed or refractory AML with an IDH2 mutation.
Agios announced a partnership with Celgene to develop metabolic immuno-oncology therapies and to license AG-221 and AG-881 to Celgene, potentially generating $120 million in drug licensing payments.
$120M source β
Agios converted from a private company to a public company with its IPO in July 2013 and subsequent listing on Nasdaq under ticker AGIO.
Agios was named among the defendants in a lawsuit against co-founder Craig Thompson alleging that he used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
βΈResearch sources Β· 8
primary sources listed
- Agios Pharmaceuticalsagios.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Agios Pharmaceuticals do?
- Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease. The company's approach is grounded in cellular metabolism research and involves close collaboration with patients and clinical partners.
- Who are Agios Pharmaceuticals's investors?
- Agios Pharmaceuticals's investors include ARCH Venture Partners, Third Rock Ventures.
- Is Agios Pharmaceuticals publicly traded?
- Yes β Agios Pharmaceuticals trades on NASDAQ under the ticker AGIO.